MiNK Therapeutics shared a post on LinkedIn:
“MiNK Therapeutics and the University of Wisconsin–Madison announced a Phase 1 clinical trial of agenT-797 to help prevent graft-versus-host disease (GvHD) following stem cell transplantation.
This non-dilutive, public-private funded study expands our off-the-shelf iNKT platform into transplantation—aiming to reduce GvHD and relapse while supporting immune reconstitution.
More posts about MiNK Therapeutics.